Linked Life Data

15170630

Source:http://linkedlifedata.com/resource/pubmed/id/15170630

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-6-1
pubmed:abstractText
We have previously reported that concanavalin A-immobilized polystyrene nanospheres (Con A-NS) could efficiently capture HIV-1 particles and that intranasal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody response in mice. In this study, to evaluate the protective effect of immunization, each three macaques was intranasally immunized with Con A-NS or inactivated simian/human immunodeficiency virus KU-2-capturing nanospheres (SHIV-NS) and then intravaginally challenged with a pathogenic virus, SHIV KU-2. After a series of six immunizations, vaginal anti-HIV-1 gp120 IgA and IgG antibodies were detected in all SHIV-NS-immunized macaques. After intravaginal challenge, one of the three macaques in each of the Con A-NS- and SHIV-NS-immunized groups was infected. Plasma viral RNA load of infected macaque in SHIV-NS-immunized macaques was substantially less than that in unimmunized control macaque and reached below the detectable level. However, it could not be determined whether intranasal immunization with SHIV-NS is effective in giving complete protection against intravaginal challenge. To explore the effect of the SHIV-NS vaccine, the remaining non-infected macaques were rechallenged intravenously with SHIV KU-2. After intravenous challenge, all macaques became infected. However, SHIV-NS-immunized macaques had lower viral RNA loads and higher CD4(+) T cell counts than unimmunized control macaques. Plasma anti-HIV-1 gp120 IgA and IgG antibodies were induced more rapidly in the SHIV-NS-immunized macaques than in the controls. The rapid antibody responses having neutralizing activity might contribute to the clearance of the challenge virus. Thus, SHIV-NS-immunized macaques exhibited partial protection to vaginal and systemic challenges with SHIV KU-2.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0146-6615
pubmed:author
pubmed:copyrightInfo
Copyright 2004 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:volume
73
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
368-77
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15170630-AIDS Vaccines, pubmed-meshheading:15170630-Administration, Intranasal, pubmed-meshheading:15170630-Animals, pubmed-meshheading:15170630-Concanavalin A, pubmed-meshheading:15170630-Female, pubmed-meshheading:15170630-Gastrointestinal Tract, pubmed-meshheading:15170630-HIV Antibodies, pubmed-meshheading:15170630-HIV Envelope Protein gp120, pubmed-meshheading:15170630-HIV Infections, pubmed-meshheading:15170630-Immunity, Mucosal, pubmed-meshheading:15170630-Immunoglobulins, pubmed-meshheading:15170630-Macaca mulatta, pubmed-meshheading:15170630-Nanotubes, pubmed-meshheading:15170630-Plasma, pubmed-meshheading:15170630-Polystyrenes, pubmed-meshheading:15170630-RNA, Viral, pubmed-meshheading:15170630-SAIDS Vaccines, pubmed-meshheading:15170630-Simian Acquired Immunodeficiency Syndrome, pubmed-meshheading:15170630-Simian immunodeficiency virus, pubmed-meshheading:15170630-Vaccination, pubmed-meshheading:15170630-Vaccines, Inactivated, pubmed-meshheading:15170630-Vagina, pubmed-meshheading:15170630-Viral Load
pubmed:year
2004
pubmed:articleTitle
Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
pubmed:affiliation
Laboratory of Primate Model, Experimental Research Center for Infectious Disease, Institute for Virus Research, Kyoto University, Kyoto, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't